Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.

Vetter ML, Johnson ME, Antons AK, Unutmaz D, D'Aquila RT.

PLoS Pathog. 2009 Feb;5(2):e1000292. doi: 10.1371/journal.ppat.1000292.

2.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Review.

PMID:
19669862
3.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
4.

[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

Fan B, Cen S, Jiang JD.

Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

PMID:
18819469
5.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

6.

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R.

Microbiol Mol Biol Rev. 2009 Jun;73(2):211-32. doi: 10.1128/MMBR.00040-08. Review.

7.

Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?

Carr JM, Davis AJ, Feng F, Burrell CJ, Li P.

Curr Drug Targets. 2006 Dec;7(12):1583-93. Review.

PMID:
17168833
8.

HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Wissing S, Galloway NL, Greene WC.

Mol Aspects Med. 2010 Oct;31(5):383-97. doi: 10.1016/j.mam.2010.06.001. Review.

9.

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51. Review.

10.

The viral infectivity factor (Vif) of HIV-1 unveiled.

Rose KM, Marin M, Kozak SL, Kabat D.

Trends Mol Med. 2004 Jun;10(6):291-7. Review.

PMID:
15177194
11.

Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Smith JL, Bu W, Burdick RC, Pathak VK.

Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Review.

12.

Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.

Huthoff H, Towers GJ.

Trends Microbiol. 2008 Dec;16(12):612-9. doi: 10.1016/j.tim.2008.08.013. Review.

13.

APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Review.

Items per page

Supplemental Content

Support Center